BioSpace News Archive

Eurofins Environment Testing Northern California: Wastewater and Eurofins Pandemic Prevention Services launched a droplet digital PCR assay for the combined quantitative analysis of SARS-CoV-2 Variants of Concern BQ.1 and BQ.1.1 in wastewater.

Greenstone Biosciences, Inc., a computational biology driven drug discovery company, announces that the Company has received a translational (TRAN4) grant funding from the California Institute of Regenerative Medicine (CIRM) (https://www.cirm.ca.gov/)

The American Cancer Society has named four new members to its board of directors, with all terms beginning on January 1, 2023.

Delaware Imaging Network, a division of RadNet, Inc., announced that it has started implementation of its new Enhanced Breast Cancer Detection service, which works in concert with a patient’s annual breast screening regimen.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Brad Moore as president and CEO of Roche Diagnostics North America, effective January 1, 2023.

Imagen Technologies, Inc. announced the U.S. Food and Drug Administration’s 510(k) clearance of the computer-assisted detection (CADe) device Aorta-CAD.

Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, has discussed with the European Medicines Agency (EMA) the design of its pivotal Phase II/III study to support a potential future marketing authorization application (MAA) for its first-in-class drug, glenzocimab.

Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacific contract research organization industry.

AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that this week the Proceedings of the National Academy of Sciences (PNAS) will publish results of a groundbreaking study demonstrating a customized, synthetic peptide’s ability to selectively detect Alzheimer’s disease.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 8,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to two newly hired employees.